Device and method for delivering a treatment to an artery

• US 20050228473A1
• Filed: 04/05/2004
• Published: 10/13/2005
• Est. Priority Date: 04/05/2004
• Status: Abandoned Application

• Current Assignee: David Brown
• Original Assignee: David Brown
• Inventors: Brown, David
• Application Number:
  US10/818,893
• Publication Number:
  US 20050228473A1
• Time in Patent Office: Days
• US Class Current: 623/1.200
• CPC Class Codes: A61F 2/88 the wire-like elements formed as helical or spiral coils forming a net-like or mesh-like structure A61F2/90
• CPC Class Codes: A61F 2210/0004 bioabsorbable
• CPC Class Codes: A61F 2250/0067 Means for introducing or releasing pharmaceutical products into the body

Abstract

A treatment device (10) for treating a treatment site (13) within a vessel (12) includes a frame (16) that is positioned in the vessel (12) at or near the treatment site (13). The vessel (12), for example, can be an artery or other internal passageway within a patient (20). The vessel (12) has a preplacement site inner diameter (28) near the treatment site (13). The treatment device (10) includes a frame (16) that moves from a contracted first configuration (30) to an expanded second configuration (236). The frame (16) has a frame outer diameter (240) at the second configuration (236) that is approximately equal to the preplacement site inner diameter (28). The frame (16) can deliver a treatment (242) to the treatment site (13).

Claims

1. A treatment device for treating a treatment site of a mammal, the mammal having a vessel that includes a placement site having preplacement site inner diameter prior to treatment, the treatment device comprising:

a frame that moves from a contracted first configuration to an expanded second configuration, the frame having a frame outer diameter at the second configuration that is approximately equal to the preplacement site inner diameter.

2. The treatment device of claim 1 wherein the frame outer diameter at the second configuration is within approximately one percent of the preplacement site inner diameter.

3. The treatment device of claim 1 wherein the frame outer diameter at the second configuration is within approximately five percent of the preplacement site inner diameter.

4. The treatment device of claim 1 wherein the frame outer diameter at the second configuration is within approximately ten percent greater than the preplacement site inner diameter.

5. The treatment device of claim 1 wherein the frame outer diameter at the second configuration is within approximately twenty percent greater than the preplacement site inner diameter.

6. The treatment device of claim 1 wherein the frame includes a coating that emits a treatment to the treatment site.

7. The treatment device of claim 1 wherein the frame is biodegradable.

8. The treatment device of claim 1 wherein the frame is hollow.

9. The treatment device of claim 8 wherein the frame includes a plurality of device apertures that extend into the hollow frame.

10. The treatment device of claim 1 wherein the frame delivers a treatment to the treatment site.

11. The treatment device of claim 10 wherein the treatment is an anti-inflammatory compound.

12. The treatment device of claim 10 wherein the treatment is a non-steroidal anti-inflammatory compound.

13. The treatment device of claim 10 wherein the treatment is a steroidal anti-inflammatory compound.

14. The treatment device of claim 10 wherein the treatment is a protease inhibitor.

15. The treatment device of claim 10 wherein the treatment is a matrix metalloproteinase inhibitor.

16. The treatment device of claim 10 wherein the treatment is an agent that increases collagen synthesis.

17. The treatment device of claim 10 wherein the treatment is an agent that increases the number of smooth muscle cells.

18. The treatment device of claim 10 wherein the treatment is an agent that reduces the number of macrophages.

19. The treatment device of claim 10 wherein the treatment includes at least one of ApoA1 (natural occurring or synthetic versions) or ApoA2 (natural occurring or synthetic versions).

20. The treatment device of claim 10 wherein the treatment is an inhibitor of nuclear factor (NF) kappa B.

21. The treatment device of claim 10 wherein the treatment is an inhibitor of p38 mitogen activator protein (MAP) kinase.

22. The treatment device of claim 10 wherein the treatment is an agonist of peroxisome proliferator-activated receptor (PPAR)-gamma.

23. The treatment device of claim 10 wherein the treatment is an inhibitor of 3-hydroxy-3-methlyglutaryl (HMG) coenzyme A (CoA) reductase.

24. A treatment device for treating a treatment site of a mammal, the mammal having a vessel that includes a placement site having a preplacement site inner diameter prior to treatment, the treatment device comprising:

a frame that moves from a contracted first configuration to an expanded second configuration, the frame delivering a treatment that includes at least one of ApoA1 (natural occurring or synthetic versions) or ApoA2 (natural occurring or synthetic versions).

25. The treatment device of claim 24 wherein the frame has a frame outer diameter at the second configuration that is within approximately twenty percent of the preplacement site inner diameter.

26. A method for treating a treatment site of a mammal, the mammal having a vessel including a placement site having a preplacement site inner diameter prior to treatment, the method comprising the steps of:

positioning a frame inside the vessel at the placement site; and

expanding the frame so that the frame has a frame outer diameter that is approximately equal to the preplacement site inner diameter.

27. The method of claim 26 wherein the step of expanding includes expanding the frame so that the frame outer diameter is within approximately one percent greater than the preplacement site inner diameter.

28. The method of claim 26 wherein the step of expanding includes expanding the frame so that the frame outer diameter is within approximately five percent greater than the preplacement site inner diameter.

29. The method of claim 26 wherein the step of expanding includes expanding the frame so that the frame outer diameter is within approximately ten percent greater than the preplacement site inner diameter.

30. The method of claim 26 wherein the step of expanding includes expanding the frame so that the frame outer diameter is within approximately twenty percent greater than the preplacement site inner diameter.

31. The method of claim 26 further comprising the step of delivering a treatment from the frame to the treatment site.